| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Reiffel JA | |
| Estes NA 3rd | |||
| Prystowsky EN | |||
| Waldo AL | |||
| DiBianco R | |||
| P2860 | cites work | Treatment of recurrent sustained ventricular tachycardia with mexiletine and disopyramide. Control by programmed ventricular stimulation | Q24563526 |
| Effects of intravenous disopyramide and quinidine on normal myocardium and on the characteristics of arrhythmias: intraindividual comparison in patients with sustained ventricular tachycardia | Q28300835 | ||
| Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program | Q28324227 | ||
| Clinical efficacy of amiodarone as an antiarrhythmic agent | Q28329369 | ||
| Sotalol-induced torsades de pointes successfully treated with hemodialysis after failure of conventional therapy | Q28334697 | ||
| Clinical safety profile of sotalol in patients with arrhythmias | Q28336076 | ||
| The long Q-T syndrome | Q33162456 | ||
| Prediction of response to class I antiarrhythmic drugs during electrophysiologic study of ventricular tachycardia | Q33173121 | ||
| Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction | Q33970406 | ||
| Approaches to sudden death from coronary heart disease | Q34051584 | ||
| A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474 | Q34234794 | ||
| Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction | Q34415281 | ||
| Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). | Q34682919 | ||
| Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors | Q35225966 | ||
| Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction | Q36601208 | ||
| Side effects from amiodarone | Q37620727 | ||
| Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial | Q37828130 | ||
| A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results | Q70220432 | ||
| Flecainide versus quinidine: Results of a multicenter trial | Q70319870 | ||
| Oral disopyramide after admission to hospital with suspected acute myocardial infarction. U. K. Rythmodan Multicentre Study Group | Q70334731 | ||
| Propafenone: a new agent for ventricular arrhythmia | Q70363021 | ||
| A randomized, double-blind, parallel group comparison of disopyramide phosphate and quinidine in patients with cardiac arrhythmias | Q70439749 | ||
| Amiodarone pulmonary toxicity | Q70535120 | ||
| Antiarrhythmic and electrophysiologic effects of oral propafenone | Q70663769 | ||
| Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog | Q70867135 | ||
| Efficacy of amiodarone for refractory supraventricular tachyarrhythmias | Q71019706 | ||
| Chronic longterm electrophysiologic study of paroxysmal ventricular tachycardia | Q71141475 | ||
| Disopyramide: evaluation of electrophysiologic effects and clinical efficacy in patients with sustained ventricular tachycardia or ventricular fibrillation | Q71674926 | ||
| Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin | Q72589995 | ||
| Comparison of the Antiarrhythmic Efficacy of Disopyramide and Mexiletine Against Stimulus-Induced Ventricular Tachycardia | Q72645027 | ||
| Comparison of acebutolol and propranolol for treatment of chronic ventricular arrhythmia: a placebo-controlled, double-blind, randomized crossover study | Q72664810 | ||
| International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Impact Research Group | Q72750686 | ||
| A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators | Q72833438 | ||
| A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators | Q72833441 | ||
| Management of recurrent ventricular tachyarrhythmias associated with Q-T prolongation | Q72892942 | ||
| Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias | Q93857521 | ||
| Pharmacology, pharmacodynamics and pharmacokinetics of sotalol | Q38137732 | ||
| Historical development of the concept of controlling cardiac arrhythmias by lengthening repolarization: particular reference to sotalol | Q38137736 | ||
| Sotalol for paroxysmal supraventricular tachycardias | Q38137740 | ||
| A perspective on ventricular arrhythmias: patient assessment for therapy and outcome | Q38138558 | ||
| The management of preexcitation syndromes | Q39771293 | ||
| Amiodarone: Historical development and pharmacologic profile | Q40156963 | ||
| Effect of antiarrhythmic drugs on mortality after myocardial infarction | Q40159319 | ||
| Clinical pharmacology and therapeutic applications of the antiarrhythmic agent amiodarone | Q40302111 | ||
| The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. | Q41114418 | ||
| Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care | Q42221096 | ||
| Long-term use of procaine amide following acute myocardial infarction | Q42230497 | ||
| Drug interactions with amiodarone | Q42241981 | ||
| Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias | Q42254976 | ||
| Amiodarone in refractory life-threatening ventricular arrhythmias | Q42259478 | ||
| The response to procainamide during electrophysiologic study for sustained ventricular tachyarrhythmias predicts the response to other medications | Q42259506 | ||
| Procainamide, disopyramide and quinidine: discordant antiarrhythmic effects during crossover comparison in patients with inducible ventricular tachycardia | Q44578419 | ||
| Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) | Q44631745 | ||
| Beta-adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation | Q45265639 | ||
| Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. | Q45992123 | ||
| Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation | Q46350852 | ||
| Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter | Q46919157 | ||
| Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation | Q50937859 | ||
| Second generation antiarrhythmic agents: have we reached antiarrhythmic Nirvana? | Q51795602 | ||
| Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. | Q54467652 | ||
| Intravenous and oral disopyramide after myocardial infarction | Q54758658 | ||
| Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. | Q55054117 | ||
| Cost-effectiveness of the implantable cardioverter-defibrillator: Effect of improved battery life and comparison with amiodarone therapy | Q61669317 | ||
| ORAL DISOPYRAMIDE IN PROPHYLAXIS OF ARRHYTHMIAS FOLLOWING MYOCARDIAL INFARCTION | Q63479595 | ||
| Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction | Q67281032 | ||
| Propranolol for patients with mitral valve prolapse | Q67554029 | ||
| Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study | Q67558033 | ||
| Treatment of ventricular arrhythmias by United States cardiologists: a survey before the cardiac arrhythmia suppression trial results were available | Q67653026 | ||
| A comparison of antiarrhythmic drugs for the suppression of ventricular ectopic depolarizations: A meta-analysis | Q67666804 | ||
| Magnitude and time course of beta-adrenergic antagonism during oral amiodarone therapy | Q67674670 | ||
| Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease | Q67725480 | ||
| Efficacy of intravenous sotalol for suppressing inducibility of supraventricular tachycardias at rest and during isometric exercise | Q67746878 | ||
| Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. A meta-analysis | Q67903871 | ||
| Evidence of a Selective Increase in Cardiac Sympathetic Activity in Patients with Sustained Ventricular Arrhythmias | Q67927748 | ||
| The incidence, magnitude, and time course of the amiodarone-warfarin interaction | Q68462467 | ||
| Effect of empiric antiarrhythmic therapy in resuscitated out-of-hospital cardiac arrest victims with coronary artery disease | Q68779133 | ||
| Amiodarone | Q68930408 | ||
| Discordance between ambulatory monitoring and programmed stimulation in assessing efficacy of class IA antiarrhythmic agents in patients with ventricular tachycardia | Q68940666 | ||
| Beta blockers in combination with class I antiarrhythmic agents | Q69004510 | ||
| Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium | Q69258719 | ||
| Comparison of the efficacy of propranolol and amiodarone in suppressing ventricular arrhythmias following myocardial infarction | Q69562817 | ||
| Concentration-response relationships of disopyramide in patients with ventricular tachycardia | Q69610231 | ||
| The role of beta blocking agents as adjunct therapy to membrane stabilizing drugs in malignant ventricular arrhythmia | Q69881361 | ||
| Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics | Q69990647 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 103-116 | |
| P577 | publication date | 1994-03-01 | |
| P1433 | published in | Clinical Cardiology | Q4502312 |
| P1476 | title | A consensus report on antiarrhythmic drug use. | |
| P478 | volume | 17 |
| Q24645167 | ABC of atrial fibrillation. Drugs for atrial fibrillation |
| Q37995463 | Amiodarone and the thyroid: a 2012 update |
| Q46504404 | Atrial fibrillation due to late amiodarone-induced thyrotoxicosis |
| Q72026045 | Desired mechanisms of drugs for ventricular arrhythmia: Class III antiarrhythmic agents |
| Q36798000 | Dysfunction of the thyroid gland during amiodarone therapy: a study of 297 cases |
| Q45935874 | Effect of grapefruit juice on amiodarone induced nephrotoxicity in albino rats. |
| Q37400220 | Incidence and pattern of thyroid dysfunction in patients on chronic amiodarone therapy: experience at a tertiary care centre in oman. |
| Q34392670 | Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment |
| Q43944332 | Iopanoic acid rapidly controls type I amiodarone-induced thyrotoxicosis prior to thyroidectomy. |
| Q51498351 | The peri-operative management of atrial fibrillation. |
Search more.